Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „differences“
Suchtreffer
Begriffe & Kennungen
Imfinzi · 4.8 · Elderly No overall differences in safety were reported between elderly (≥ 65 years) and younger patients.
Eintrag öffnenImfinzi · 4.8 · In first line metastatic NSCLC patients in the POSEIDON study, some differences in safety were reported betwee
Eintrag öffnenImfinzi · 4.8 · In resectable NSCLC patients in the AEGEAN study, some differences in safety were reported between elderly (≥
Eintrag öffnenIndividualität
Eintrag öffnenItuxredi · 4.8 · In GPA/MPA Study 2, no clinically meaningful differences between the two treatment arms or decreases in total
Eintrag öffnenJascayd · 4.5 · No clinically relevant differences in the pharmacokinetics of the following active substances were observed wh
Eintrag öffnenKaftrio · 4.8 · With the exception of sex differences in rash, the safety profile of IVA/TEZ/ELX in combination with IVA was g
Eintrag öffnenKaftrio · 4.8 · With the exception of sex differences in rash, the safety profile of IVA/TEZ/ELX in combination with IVA was g
Eintrag öffnenKovaltry · 4.8 · Paediatric population In the clinical studies no age-specific differences in ADR were observed except for FVII
Eintrag öffnenLazcluze · 4.5 · No clinically relevant differences in lazertinib pharmacokinetics were observed when co-administered with gast
Eintrag öffnenLenvima · 4.8 · The median time to first onset in lenvatinib-treated patients was 10.1 weeks. No differences between lenvatini
Eintrag öffnenLoqtorzi · 4.8 · No overall differences in safety were observed between patients ≥ 65 years of age and younger patients receivi
Eintrag öffnenLumykras · 4.8 · Elderly In clinical studies, no overall differences in safety or efficacy were observed between elderly patien
Eintrag öffnenLyumjev (previously Liumjev) · 4.8 · There were no clinically significant differences in the frequency of hypoglycaemia with administration of Lyum
Eintrag öffnenLyumjev (previously Liumjev) · 4.8 · There were no clinically significant differences in the frequency of hypoglycaemia with administration of Lyum
Eintrag öffnenMabThera · 4.8 · In GPA/MPA Study 2, no clinically meaningful differences between the two treatment arms or decreases in total
Eintrag öffnenMektovi · 4.5 · While encorafenib is a relatively potent reversible inhibitor of UGT1A1, no differences in binimetinib exposur
Eintrag öffnenMembranpotentiale
Eintrag öffnenMirvaso · 4.8 · Other special populations Elderly patients 5 No meaningful differences in the safety profiles were observed be
Eintrag öffnenNepexto · 4.8 · There were no differences in rates of infection among patients treated with etanercept and those treated with
Eintrag öffnen